NeOnc Schedules Phase 2 Meeting for NEO212
NeOnc will meet with FDA in November to review its Phase 2 design for the gastric cancer drug NEO212. The company reported encouraging clinical data from the previous Phase 1 trials.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed